Mp04-12 Comparing Methocarbamol to Oxybutynin for Stent Colic a Prospective Randomized Controlled Trial

You have accessJournal of UrologyStone Disease: Surgical Therapy (including ESWL) I (MP04)1 May 2024MP04-12 COMPARING METHOCARBAMOL TO OXYBUTYNIN FOR STENT COLIC – A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL Perry Xu, Nick Dean, Alyssa McDonald, Allaa Fadl-Alla, and Amy Krambeck Perry XuPerry Xu , Nick DeanNick Dean , Alyssa McDonaldAlyssa McDonald , Allaa Fadl-AllaAllaa Fadl-Alla , and Amy KrambeckAmy Krambeck View All Author Informationhttps://doi.org/10.1097/01.JU.0001008708.00982.a9.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Stent colic presents as a challenging complication following ureteroscopy. Several pain regimens are purported to reduce stent colic. We sought to prospectively compare methocarbamol – a skeletal muscle relaxant – to oxybutynin – an anticholinergic – for mitigation of stent colic following retrograde intrarenal surgery (RIRS) for nephrolithiasis. METHODS: Patients undergoing RIRS for nephrolithiasis with stent placement at a single institution were prospectively randomized to receive either methocarbamol 750 mg Q6 PRN versus oxybutynin 10 mg XL QHS in addition to standard postoperative non-narcotic medications. Preoperatively, baseline characteristics were obtained, including visual analogue scale (VAS) scores and PROMIS 3a and 6 scores (patient-reported outcomes measurement information system). VAS and PROMIS scores were then obtained from patients postoperatively via daily surveys. On postoperative day 15 and 30, additional surveys were sent inquiring regarding complications and ER visits. RESULTS: 60 patients were recruited with 30 randomized to receive methocarbamol and 30 to receive oxybutynin postoperatively. Patients had a comparable stone burden and baseline characteristics (Table 1). Patients receiving methocarbamol were more likely to be female (p=0.012). Preoperatively, patients randomized to oxybutynin had a higher total PROMIS and VAS pain score (p=0.040, p=0.026). Postoperatively, there were no differences on daily PROMIS and VAS scores between those receiving methocarbamol and those receiving oxybutynin. There were no differences in postoperative day 15 and 30 surveys regarding ER visits and complications. CONCLUSIONS: There were no significant differences in utilization of methocarbamol versus oxybutynin for management of postoperative stent colic following ureteroscopy. Providers may determine which medication to use based on the more favorable side-effect profile. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e39 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Perry Xu More articles by this author Nick Dean More articles by this author Alyssa McDonald More articles by this author Allaa Fadl-Alla More articles by this author Amy Krambeck More articles by this author Expand All Advertisement PDF downloadLoading ...